Sofia M., Wang Z. Trends in Antiviral Drug Development Vol 2. 2025

Textbook in PDF format

Hard-to-find insights from industry professionals on success strategies for developing the next generation of antiviral blockbuster drugs.
Presented by industry professionals with a track record of discovering new drugs and treatments, Trends in Antiviral Drug Development describes successful development efforts for antiviral compounds and therapies that have entered the market or are currently in clinical trials. Viruses are ordered by their target tissue, in line with contemporary drug development that focuses on tissue-targeted therapeutics. Other key trends in antiviral therapy, such as the effort to develop long-acting drugs, are described for each virus type, enabling readers to follow the current and future state in this core area of contemporary drug development.
Trends in Antiviral Drug Development includes discussion on:
Novel drugs against herpes viruses as well as the breakthrough drugs that cured HCV.
siRNA therapeutics, a new antiviral modality, and the drug candidates that are progressing toward achieving an HBV cure.
Drugs targeting viral entry, such as in HIV entry through attachment, co-receptor binding, and fusion.
Novel therapeutics against tropical diseases such as dengue fever and monkey pox.
Trends in Antiviral Drug Development is an essential read for medicinal chemists, pharmaceutical chemists, virologists, and all professionals seeking to understand new ideas and approaches to combat the ever-expanding universe of viral infections.
Introduction: Successes and Challenges in Antiviral Drug Development
Human Herpes Viruses
Letermovir for the Prevention of CMV Infection in Transplant Recipients
Discovery and Development of the Helicase–Primase Inhibitor Pritelivir for the Treatment of Immunocompromised Patients with Resistant HSV Infection
Immunodeficiency Virus
The Discovery and Early Development of the HIV-1 Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)
The Discovery and Development of Islatravir (4′-Ethynyl-2-fluoro-2′-deoxyadenosine [EFdA], MK-8591)
Hepatitis Viruses
Discovery of the RNA Interference Therapeutic Imdusiran, a GalNAc-conjugated siRNA
Discovery and Development of ARO-HBV/JNJ-3989
The Discovery and Development of Sofosbuvir as the Backbone of HCV Curative Therapies
The Discovery and Development of Harvoni and Epclusa: Ending the Interferon Era; Curing All Hepatitis C Genotypes
Respiratory Viruses
Presatovir: A Once-daily Oral Respiratory Syncytial Virus Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus Infection in Adults and Infants
Remdesivir for the Treatment of COVID-19 and Other Viral Infections with Pandemic Potential
Discovery and Clinical Development of Ensitrelvir: An Oral SARS-CoV-2 3CL Protease Inhibitor for the Treatment of COVID-19
Discovery and Development of VV116: A Novel Oral Nucleoside Anti-SARS-CoV-2 Drug
Molnupiravir
Tropical Disease Viruses
Development of a Novel Class of Highly Potent Dengue Virus Inhibitors: From Hit to the Clinical Candidate Mosnodenvir
Orthopoxvirus
Discovery and Development of Brincidofovir